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Abstract: Strongyloides stercoralis infections have a
worldwide distribution with a global burden in terms of
prevalence and morbidity that is largely ignored. A public
health response against soil-transmitted helminth (STH)
infections should broaden the strategy to include S.
stercoralis and overcome the epidemiological, diagnostic,
and therapeutic challenges that this parasite poses in
comparison to Ascaris lumbricoides, Trichuris trichiura, and
hookworms. The relatively poor sensitivity of single stool
evaluations, which is further lowered when quantitative
techniques aimed at detecting eggs are used, also
complicates morbidity evaluations and adequate drug
efficacy measurements, since S. stercoralis is eliminated in
stools in a larval stage. Specific stool techniques for the
detection of larvae of S. stercoralis, like Baermann’s and
Koga’s agar plate, despite superiority over direct tech-
niques are still suboptimal. New serologies using recom-
binant antigens and molecular-based techniques offer
new hopes in those areas. The use of ivermectin rather
than benzimidazoles for its treatment and the need to
have curative regimens rather than lowering the parasite
burden are also unique for S. stercoralis in comparison to
the other STH due to its life cycle, which allows
reproduction and amplification of the worm burden
within the human host. The potential impact on STH of
the benzimidazoles/ivermectin combinations, already
used for control/elimination of lymphatic filariasis, should
be further evaluated in public health settings. While
waiting for more effective single-dose drug regimens and
new sensitive diagnostics, the evidence and the tools
already available warrant the planning of a common
platform for STH and S. stercoralis control.
Introduction
Soil transmitted helminthiasis (STH) affects up to one in four
individuals in the world, disproportionately affecting impoverished
populations without access to adequate water, sanitation, and
opportunities for socioeconomic development [1]. Efforts to
control the impact of STH are based on public health
interventions that have periodic anthelminthic treatment, primar-
ily of children, as the foundation for school or community based
interventions. Attention has historically focused on just four species
of STH, A. lumbricoides, T. trichiura, and hookworms (Ancylostoma
duodenale and Necator americanus). Due to the challenge of measuring
the disease burden and monitoring the control intervention, the
role of S. stercoralis, which is as much an STH as the other four by
its standard definition, has been neglected in the repertoire of
strategies to reduce the burden of these neglected tropical diseases
(NTDs) through public health interventions [2]. Main character-
istics of STH and S. stercoralis infections are illustrated in Table 1.
The aim of the present review is to discuss why S. stercoralis has
been overlooked in the management of STH through large-scale
administration of anthelminthic drugs (preventive chemotherapy),
and to highlight the aspects of this helminthic infection that justify
its inclusion in a more comprehensive approach to STH control.
Among the reasons for the traditional approach, which excludes/
ignores S. stercoralis, are the non-standard approaches needed to
diagnose S. stercoralis, the different drugs and treatment regimens
needed, and the paucity of data on subtle and chronic morbidity
that sustain the lack of clear goals for an intervention targeting the
infection [3–5]. The description of the difficulties described in the
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following sections of this article should however be viewed as a
challenge to overcome rather than a justification for the
maintenance of the status quo. This challenge will most likely
find success through the current strategy of aggregating and
combining treatments and integrated control rather than devel-
oping single disease interventions when feasible [6].
Clinical Importance of S. stercoralis
Strongylodiasis is best known in the developed world for the
severe consequences of the hyperinfection syndromes linked to
immunosuppression caused by diseases like lymphomas, leukemi-
as, or the use of corticosteroids [7]. This clinical entity, which in
resource-poor countries is probably associated with widespread
malnutrition, is probably just the tip of an iceberg of unknown size.
Defining the denominator of patients infected by S. stercoralis and
the assessment of associated morbidity including the proportion of
those that suffer hyperinfection in a given community is essential
to better identify risk factors, understand pathogenesis, and plan
control measures in its natural setting.
As noted by other authors, the disability-adjusted life year
(DALY) system represents a poor estimate of the true burden and
morbidity of STH overall [8]. For S. stercoralis, this is further
complicated by the challenges of clinical follow-up, as its infection
does not trigger anemia nor does it have any clinical marker that
can be easily diagnosed and monitored. Attempts to demonstrate
the subtle morbidity associated with S. stercoralis infections are also
limited by the difficulties in correctly identifying uninfected control
groups with the poorly sensitive direct diagnostic tools such as stool
examinations that are the current standard. A recent report was
however able to identify through questionnaires and stool
evaluations that individuals infected by S. stercoralis were more
likely to complain of stomach ache [9]. Pathology evaluations of
the gastrointestinal tract indicate that there is a lack of lesions in
the mucosa in most infections, which only becomes apparent in
severe infections. These changes include an inflammatory response
that ranges from congestive catarrhal enteritis to an edematous
and ulcerative enteritis, reflecting the wide spectrum of symptoms
found in endemic areas, with a significant proportion of
individuals without acute intestinal complaints [10,11]. Non
specific urticaria, a bothersome symptom, is a very frequent
finding (up to 100% in a report of 52 cases), but is rarely reported
spontaneously by the infected individuals [12]. More information
on the impact on the quality of life impaired by these infections,
particularly in endemic populations rather than just in travelers
[9], should be the basis for the control of strongyloidiasis with the
goal of reducing the related morbidity, and not just as a means of
lowering the chances of developing hyperinfection. In summary,
without good reliable data on infection, morbidity, and indisput-
able causal links between them, it has been challenging to make
the public health argument for the response against S. stercoralis.
Diagnostic Challenges
Most of the difficulties posed in the measurement of S. stercoralis
infections and its consequences rely on the challenging aspects of
its diagnosis, which ultimately affect its incorporation into a
control package with the other STH. In terms of diagnostics, Kato
Katz (the diagnostic method recommended by WHO) and
McMaster are techniques made to detect (and quantitate) eggs,
which do not detect S. stercoralis larvae [13]. Even new
developments in this area, like the FLOTAC, an improvement
of the McMaster, focus on egg detection and fail to detect the
presence of S. stercoralis, which is diagnosed in stool exams through
the identification of its larval stages [14,15]. At present the two
most appropriate diagnostic tools for the diagnosis of S. stercoralis
are the Baermann and the Harada Mori methods, although their
sensitivity is not optimal; the agar plate method is more sensitive
but also more expensive and laborious [3].
There are also important therapeutic implications in terms of
clinical trial design and evidence-based recommendations that
emerge from the challenges of diagnosing S. stercoralis. Starting
with the inclusion criteria for such trials, categorizing a patient as
positive for S. stercoralis is a lot easier than categorizing that same
patient as negative or cured using either one, two, or three stool
exams as test of cure, as has been very carefully demonstrated in a
well controlled population studied with eight stool exams [16].
Such issues should question the interpretation and conclusions of
every clinical efficacy trial that uses these stool techniques as test of
cure. These challenges stress the need for a new generation of
diagnostics. The incorporation of real-time PCR assay for multiple
STH, including S. stercoralis, could be an improvement to
overcome this obstacle due to its reported high sensitivity,
although this warrants further validation [17].
The complexities in diagnosis have led to the challenge of
demonstrating the burden of disease of this parasite and this may
explain why S. stercoralis is still neglected from the public health
perspective. Innovative approaches for the diagnosis of STH aim
at solving the weaknesses of traditional methods that depend on
stool collection; such weaknesses are not only linked to the low
sensitivity and specificity of the different techniques but also to the
difficulties in getting several stool samples per patient for analysis.
Table 1. Principal features of STH and S. stercoralis.
Feature Major STH S. stercoralis
A. lumbricoides T. trichiura A. duodenale N. americanus
Multiplication within the host/
autoinfection
2 2 2 2 +++
Morbidity acute/chronic +/+ ++ +/+++ ++/++++ +/+++ ++/++++
Potential fatality + 2 ++ + ++++
Main diagnostic stage Egg Egg Egg Egg Larvae
Therapeutic goal Cure or decreasing
worm load
Cure or decreasing
worm load
Cure or decreasing
worm load
Cure or decreasing
worm load
Cure
Outcome measurement Cure rate and egg
reduction rate
Cure rate and egg
reduction rate
Cure rate and egg
reduction rate
Cure rate and egg
reduction rate
Cure rate
doi:10.1371/journal.pntd.0002165.t001
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While it is clear that, especially for S. stercoralis, several samples
increase sensitivity [16], large scale programs have accepted the
use of a single sample, given the complexity and costs of collecting
and processing multiple samples. This results in significant
underestimations of the true prevalence of infection while not
completely eliminating the difficulties of collecting stools.
S. stercoralis serologic assays can simplify the diagnosis of this
infection and overcome the poor sensitivity of single stool exams,
both for diagnosis of individual patients and also for defining
infection prevalence at the community level [18]. The introduc-
tion of assays based on recombinant antigens that can be produced
in large quantities offers attractive alternatives to the use of crude
antigen, which requires the maintenance of laboratory animals
with chronic infections or stool collections from infected individ-
uals for antigen production. Recent field evaluations with a 31-
kDa recombinant antigen (termed NIE), which has no cross
reactivity with other STH, have shown improved sensitivity
compared to a variety of stool evaluations in a single stool exam
[19]. A commercial ELISA assay with recombinant antigen could
be the ideal product for S. stercoralis diagnosis, as other methods
either need the cumbersome collection of crude antigen, or like the
immunofluorescence antibody test (IFAT) are too dependent on
the operator skills and on the performing laboratory, and are thus
difficult to standardize and replicate on a large scale. It is still
unknown whether antibody levels measured with any of these
assays correlate with worm burden. The possibility of using these
assays to conduct sero-surveys is currently limited to S. stercoralis
due to the lack of antigens for A. lumbricoides, T. trichiura, or
hookworms with similar performance, and calls for further
research in the search of antigens for the other STH. The
available diagnostics test for STH and S. stercoralis are illustrated in
Table 2.
Treatment Challenges
Current therapy is another issue to be revised if S. stercoralis is to
be considered in the spectrum of targeted parasites amenable to
public health control. Neither of the recommended drugs for use
in large scale interventions to control STH infections, which
include the benzimidazoles albendazole and mebendazole,
levamisole, and pyrantel/oxantel have any significant activity
against S. stercoralis, at least in single doses as recommended for
preventive chemotherapy interventions [1,20]. In terms of
treatment goals, while lowering parasite burden in the group of
individuals with moderate and high worm burdens is, from an
arguable public health point of view, a reasonable goal for A.
lumbricoides, T. trichiura, and hookworms [21,22], this is not true for
S. stercoralis. The peculiar life cycle of S. stercoralis, and specifically
this worm’s unique (among STH) ability to reproduce within the
human host, makes anything but parasitologic cure a treatment
failure and therefore, any measure of parasite load reduction
would not be a measure of success as for the other STH [23]. This
last reason is what makes a drug like albendazole, with cure rates
of approximately 40% when used in single-dose regimens, an
unsatisfactory option for S. stercoralis [24,25]. This difference in life
cycles results in having at a maximum one adult worm per each
invasive egg or larva that infects the host for A. lumbricoides, T.
trichiura, and hookworms, but infinite numbers (resembling the
situation in protozoan and bacterial infections) for S. stercoralis.
Larvae from this parasite hatch in the stool, rapidly evolve into
infective L3 filariform larvae, and re-infect the same individual,
perpetuating the infection in healthy hosts and through the
expansion of this re-infection step, overwhelm the host in the
context of immune suppression [7]. In reference to immune
protection, it is clear that acquired immunity develops in humans
to infection with S. stercoralis, on the basis of the antibody responses
that develop to the infection [26]. Furthermore, acquired
protective immunity to the infection has been described exten-
sively in animal models [27]. However, the lifelong nature of
infections in humans argues that host immunity may limit worm
burden, but it is not sufficient to eradicate it.
Ivermectin, the current standard of care for the treatment of S.
stercoralis infections, showed superiority against thiabendazole in
terms of safety and similar efficacy [28,29]. Due to its widespread
Table 2. Diagnostic techniques for the diagnosis and quantification of STH.
Type of Method Technique S. stercoralis STH
A. lumbricoides Hookworms T. trichiura
Parasitological methods Direct exam + + + +
Sedimentation concentration ++ ++ ++ ++
Baermann (+/2
charcoal culture)
+++ 2 +a 2
Agar plate ++ 2 +a 2
Harada Mori ++ 2 +a 2
McMaster — +++b +++b +++b
Kato Katz — +++b +++b +++b
FLOTAC — +++b +++b +++b
Serology Crude antigen ELISA +++ 2 2 2
IFAT +++ 2 2 2
Recombinant antigens
(LIPS, ELISA)
+++ 2 2 2
PCR ++ ++ ++ ++
aFor larvae detection and species identification.
bQuantitative techniques.
IFAT, indirect immunofluorescence antibody test; LIPS, luciferase immunoprecipitation systems.
doi:10.1371/journal.pntd.0002165.t002
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use in lymphatic filariasis and onchocerciasis control programs,
ivermectin has a well determined safety profile. It is however
restricted in pediatric populations, limiting its use according to
different criteria of age, weight, and/or height (older than either 3
or 5 years old, taller than 90 cm, or above 15 kg of weight)
depending on the country. The reasons for this are related to
potential toxicity in the central nervous system seen most
commonly but not only in Collie dogs, which is however related
to a genetic predisposition of those dog species and has not been
observed in humans [30]. The exposure of breastfed infants during
the treatment of their mothers (ivermectin is contraindicated in
pregnancy and the first week post partum [13]), does not add
significant information about exposure in these children despite
the significant passage through milk (40% of the plasma levels),
since this amount has been calculated to be just 2 to 4 mg/kg for
the average infant—a dose 50 to 100 times less than the usual dose
[31]. Emerging data suggest that the use of this drug could be a
powerful tool to prevent rheumatic fever through the treatment of
scabies [32], a reasonable option for head lice, and a component of
a combination regimen with mebendazole or albendazole for the
treatment of T. trichiura [33]. Thus ivermectin is turning into an
essential drug in the pediatric pharmacopeia. Hence, demonstrat-
ing the safety of this drug in the group of 3 to 5 year olds to realize
its full therapeutic possibilities is a reasonable and important step.
Despite the widespread use of ivermectin in many countries
endemic for lymphatic filariasis, onchocerciasis, and STH,
unfortunately very few studies have looked at the impact of those
interventions on strongyloidiasis in areas where this infection is co-
endemic [34].
Initiatives like the one by WHO proposing multicentric,
properly controlled, powered, and monitored clinical trials
employing medicines from a known and reputable drug manu-
facturer are a necessary initial step to acquire definitive data about
all the anthelminthics included in the essential drugs list
(albendazole, mebendazole, levamisole, and pyrantel) in order to
produce biologic and statistically sound evidence. This process has
already been used to generate data on albendazole [22], is ongoing
with mebendazole, and is in the pipeline for pyrantel/oxantel.
Similar initiatives with ivermectin in developed countries against S.
stercoralis in settings where infection can be properly controlled and
reinfection can be prevented, are needed as starting points to
produce solid evidence. A multicentric randomized trial in a
clinical setting to assess efficacy and safety of different therapeutic
regimens of ivermectin (single dose of 200 mg/kg versus 200 mg/kg
for 2 consecutive days, repeated 14 days after the first dose) is
ongoing (ClinicalTrials.gov Identifier: NCT01570504) and will
give valuable answers to clinical and public health questions. In
addition, this clinical trial will answer the question on the most
sensitive and specific serological diagnostic assay and its value as
marker of cure. Therapeutic efficacies with different drug
regimens and combination for STH and S. stercoralis infections
are illustrated in Table 3.
Control of S. stercoralis
Epidemiologic studies looking into the distribution of S. stercoralis
in communities have shown prevalence peaks in adolescents,
remaining stable in adults, with a similar distribution as
hookworms. Some studies have shown no gender difference and
others have found it more prevalent in males, possibly representing
differential exposure [9,35,36]. Findings of higher burden in the
adult population challenge the current policies of focusing
interventions (and also drug donations) in school-age and
preschool-age children. WHO guidelines offer a clear stepwise
approach to the community based treatment of STH through
anthelminthic therapy, with the 20% and 50% thresholds of
combined prevalence for any of the major STH triggering the use
of preventive chemotherapy interventions once or twice a year,
respectively [13]. While this strategy is in use around the world
and delivering measurable benefits, there is room for further study
of this strategy in order to provide scientific support to the
expansion or modification of this approach. Among these unsolved
areas is the definition of an appropriate prevalence threshold that
should trigger community treatments for S. stercoralis, considering
the particularities of the life cycle and treatment goals discussed
above. The search for new diagnostic tools for S. stercoralis should
not hamper the development of strategies for the implementation
of control programs. The use of the available, albeit moderately
sensitive, direct diagnostic tools in sentinel sites should allow
predicting a good enough picture of the distribution of S. stercoralis
that could justify a therapeutic intervention. More evidence and
data are needed, however, to define such prevalence thresholds.
Most published literature concerning this helminth (fewer than
150 articles) refers to clinical cases of hyperinfection, most of them
from industrialized and middle-income countries. A crude
estimate of this number with the quoted worldwide prevalence
of 30 million to 100 million cases of strongyloidiasis means that for
every case report there are approximately 200,000 to 700,000
cases, mainly in developing countries [37]. Another issue currently
not contemplated in the recommendations for preventive chemo-
therapy programs against STH in humans, in contrast to what
happens in veterinary medicine, is the timing of treatment based
on climatic factors in order to prevent the emergence and
proliferation of resistant clones through the maintenance of ‘‘wild
type’’ clones in refugia [38]. Caution should however be used
while trying to derive conclusions from clinical trials in the setting
of public health interventions where causality and the weight of
each component of the control programs must be considered.
Controversies around meta-analyses aimed at answering key
questions about STH management highlight the problems faced
by trying to apply the evidence based medicine standards
constructed mainly on the results and conclusions of randomized
clinical trials, to complex interventions that are usually multiple
and influenced by several factors, which sometimes are setting-
specific and prevent the generalizability of the findings [39].
Translating results of properly powered and designed trials to
define safety and efficacy into implementation programs, is
dependent on the ability to measure the effectiveness of programs
to facilitate proper decision making. The use of established
primary care programs might offer opportunities to tailor universal
recommendations by moving into trials and field interventions
where multiple dosing regimens, pharmacovigilance, and moni-
toring activities could be implemented. An example of this model
is ongoing in northwestern Argentina, where in the Department of
Oran, Province of Salta, monitoring and evaluation of STH
preventive chemotherapy interventions is based on a regimen
containing albendazole and ivermectin. This program, combines
stool analysis with a newly validated NIE-ELISA serologic assay
(for S. stercoralis), and is being implemented by a primary care
network with provincial coverage that through sanitary agents
ensures at least four house visits annually. Community based
interventions like this are allowing the potential integration of
deworming and monitoring activities into the care of other NTDs
(leishmaniasis, dengue, Chagas, and leprosy are prevalent in the
area) and in a larger picture, public health care in all its aspects
[36].
Overlapping endemicities, many with shared risk factors are the
rule; new tools with the capacity to generate epidemiological and
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program impact data across a broader spectrum of target
organisms are therefore needed. A multiplex bead-based technol-
ogy that measures antibody responses to several agents in a single
serum sample in a single well, is able to potentially produce up to
9,600 pieces of data from a single 96-well plate, with the possibility
of evaluating a wide variety of health determinants simultaneously
[40]. Such an assay might open up new options to program
monitoring and evaluation efforts [41]. A similar approach
through the use of molecular biology techniques measuring stool
DNA in assays set for multiple enteric parasites (Multiplex)
including S. stercoralis, Entamoeba histolytica, Giardia intestinalis, and
Cryptosporidium spp. is also a promising tool for the evaluation of
STH. This assay has an improved sensitivity in a single stool
specimen, as shown by Basuni et al. in a real-time PCR assay for
the simultaneous detection of A. duodenale, N. americanus, A.
lumbricoides, and S. stercoralis [17]. PCR is a new diagnostic tool
that still requires proper evaluation in the diagnosis of S. stercoralis
infections, particularly in field studies, with its limitations and
potential challenges. With reference to the intermittent shedding
of S. stercoralis larvae in stools, it is still unclear whether this is true
in absolute terms or if it is a phenomenon observed due to the
fluctuating levels of larval output above and below the level of
sensitivity of the different stool techniques, and may therefore, be
overcome by this molecular-based sensitive technique. Multiplex
molecular diagnostic devices measuring parasite DNA in stools
can measure an array of intestinal parasites, and could give a full
picture of the polyparasitism in endemic communities [42]. Such
tools could be the new frontier of diagnostics that lay the
foundation for innovative therapeutic options.
A great deal of progress has been made on development of
vaccines against human infections with hookworms, beginning
with animal studies and currently involving clinical trials [43].
Efforts to develop vaccines against human infection with S.
stercoralis have been limited, although there have been excellent
results in an animal model using a single recombinant diagnostic
antigen as the vaccine against S. stercoralis [44]. The efficacy of this
vaccine in humans has not been tested.
There is a variety of areas of research that need to provide the
necessary answers to improve the actions taken against STH and
identify the new implementation components that would make a
comprehensive approach to STH and S. stercoralis control feasible.
As an initial step, the identification of the most adequate diagnostic
tools along with the safest and most effective treatment regimen to
be implemented in a package with the other STH appears to be
the most urgent need; this should be followed by the development
and incorporation of new strategies and technology for the
monitoring and evaluation. Drugs are at the center of such
investigations: recent progress in the availability of mebendazole
and albendazole through donation programs and the commitment
of funds for their distribution pose a new emphasis in the need to
identify the biomedical answers that will allow the best utilization
of these newly available resources [45]. Ivermectin and albenda-
zole, historically used for lymphatic filariasis control/elimination,
already have a spectrum of activity against multiple parasites,
including STH and S. stercoralis, intestinal protozoa, and ectopar-
asites, and the potential impact of this combination with different
formulations and dosages should be further evaluated in public
health settings.
Table 3. Cure rates and egg reduction rates (mean %) of anthelminthics recommended by WHO, administered in single dose
against STHs.
Drug Dose Rate S. stercoralisa A. lumbricoides Hookworms T. trichiura Refs
Albendazole 400 mg CR — 88–98.4 78.4–100 10–52.7 [22,24,33,46]
— ERR — 86.5–100 64.2–100 40.3–50.8 —
Mebendazole 500 mg CR — 95–96.5 22.9 19–36 [24,33]
— ERR — — — 66.7–92.8 —
Ivermectin 200 mg/kg CR 56.6–68.1 78.4–94.2 — 35.1–44.3 [28,46,47]
— ERR — 94.3–100 — 42.7–86.8 —
Pyrantel 10 mg/kg CR — 88 31 28.1 [24]
— ERR — 87.9 56.4–75 52 —
Levamisole 2.5 mg/kg or 80 mg CR — 91.5 10–38.2 9.6 [24]
— ERR — — — 41.5 —
Albendazole/ivermectin 400 mg/200 mg/kg CR 56.6–68.1b 78.1–100 78.4–100b 38–79.6 [33,46,47]
— ERR — 99.5–100 100 68–97.5 —
Mebendazole/ivermectin 500 mg/200 mg/kg CR 56.6–68.1b 96.5b 22.9b 55.196.7 [33]
— ERR — — — — —
aStudies considered are only those that used antibody responses rather than parasitologic evaluations as test of cure.
bIn view of the lack of control studies with these combinations, values refer to the efficacy observed with the administration of the most effective drug of the
combination, used as monotherapy.
CR, cure rates; ERR, egg reduction rates.
doi:10.1371/journal.pntd.0002165.t003
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